Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firibastat in difficult-to-treat/resistant hypertension
NCT04277884Phase 3Completed
- Sponsor
- Quantum Genomics
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of firibastat in hypertension (HTN), sponsored by Quantum Genomics. Started Jun 2020; status: completed.
02
Drugs
firibastat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04277884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277884.